Kerala Ayurveda

Who are the top shareholders of the Kerala Ayurveda?

The top shareholders of Kerala Ayurveda are Katra Holdings Ltd with 53.97%, followed by individual investors at 32.23%, and Porinju Veliyath as the largest public shareholder at 5.18%. Mutual funds hold 0.02%, and there are no foreign institutional investors.

The top shareholders of Kerala Ayurveda include Katra Holdings Ltd, which holds the largest share at 53.97%. This is followed by individual investors, who collectively own 32.23% of the company. The highest public shareholder is Porinju Veliyath, with a holding of 5.18%. Additionally, there is a small percentage of shares held by mutual funds, specifically 0.02%, and no foreign institutional investors (FIIs) currently hold shares in the company.

Who are in the management team of Kerala Ayurveda?

As of March 2022, the management team of Kerala Ayurveda includes Ramesh Vangal (Chairman), K Anilkumar (Whole-time Director), Anand Subramanian, Gokul Patnaik, and several independent directors, along with Ashitha B R as Company Secretary.

As of March 2022, the management team of Kerala Ayurveda includes the following individuals:<BR><BR>1. Ramesh Vangal - Chairman (Non-Executive)<BR>2. K Anilkumar - Whole-time Director<BR>3. Anand Subramanian - Director<BR>4. Harish Menon - Independent Director<BR>5. Gokul Patnaik - Director<BR>6. S Krishnamurthy - Independent Director<BR>7. Ashitha B R - Company Secretary & Compliance Officer<BR>8. Shilpa Kiran Gududur - Independent Director<BR>9. Rajesh Sharma - Independent Director<BR><BR>These members play various roles in the governance and management of the company.

What does Kerala Ayurveda do?

Kerala Ayurveda Ltd manufactures Ayurveda products and operates in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 31 Cr and a net loss of 16 Cr, with a market cap of Rs 547 Cr.

Overview: <BR>Kerala Ayurveda Ltd is engaged in the manufacture of Ayurveda products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>Kerala Ayurveda Ltd was established on 6th July 1992. The company has recently reported net sales and profit for the quarter ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 31 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -16 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 547 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 7.09 <BR>Return on Equity: -154.90% <BR>Price to Book: 57.69<BR><BR>Contact Details: <BR>Address: VII/415 Nedumbassery, Athani P O Aluva Ernakulam Kerala : 683585 <BR>Tel: 91-484-2476301/2/3/4 <BR>Email: info@keralaayurveda.biz <BR>Website: http://www.keralaayurveda.biz

Has Kerala Ayurveda declared dividend?

No Dividend History Available

Who are the peers of the Kerala Ayurveda?

Kerala Ayurveda's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ind-Swift Labs, Albert David, Medico Remedies, and Accent Microcell. While Kerala Ayurveda has below average management risk and growth, its 1-year return is 42.32%, higher than Ind-Swift Labs but lower than Divi's Lab's 51.69%.

Peers: The peers of Kerala Ayurveda are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ind-Swift Labs., Albert David, Medico Remedies, Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is present at Albert David, Medico Remedies, Accent Microcell, and the rest. Below average management risk is noted for Kerala Ayurveda and Ind-Swift Labs. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen in Kerala Ayurveda, Ind-Swift Labs., and Torrent Pharma. Average growth is found at Medico Remedies, and good growth is noted for Accent Microcell. Capital structure is excellent for Sun Pharma.Inds., Cipla, Divi's Lab., and Dr Reddy's Labs, while good capital structure is observed at Medico Remedies, and below average capital structure is noted for Kerala Ayurveda, Ind-Swift Labs., and Torrent Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Ind-Swift Labs. at -21.31%. Kerala Ayurveda's own 1-year return is 42.32%, which is significantly higher than Ind-Swift Labs. but lower than Divi's Lab. Additionally, peers with negative six-month returns include Ind-Swift Labs., Albert David, and Accent Microcell.

Is Kerala Ayurveda overvalued or undervalued?

As of May 27, 2025, Kerala Ayurveda is considered risky and overvalued with a PE ratio of -37.04 and an EV to EBITDA of -122.35, significantly lagging behind peers like Sun Pharma and Cipla, despite a strong 1-year stock return of 55.01% compared to the Sensex's 7.58%.

As of 27 May 2025, the valuation grade for Kerala Ayurveda has moved from very expensive to risky, indicating a significant shift in its market perception. The company appears to be overvalued, with a PE ratio of -37.04, an EV to EBITDA ratio of -122.35, and a Price to Book Value of 57.37. These ratios suggest that the company's earnings and asset valuations are not aligned with its current market price.<BR><BR>In comparison to its peers, Kerala Ayurveda's metrics are starkly unfavorable. For instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93, both indicating more robust valuations. The company's recent stock performance has outpaced the Sensex, with a 1-year return of 55.01% compared to the Sensex's 7.58%, but this does not mitigate its current overvaluation status.

How big is Kerala Ayurveda?

As of 24th July, Kerala Ayurveda Ltd has a market capitalization of 673.00 Cr and reported Net Sales of 121.47 Cr with a Net Profit loss of 13.03 Cr over the latest four quarters. The balance sheet for March 2024 shows Shareholder's Funds of 32.16 Cr and Total Assets of 140.71 Cr.

As of 24th July, Kerala Ayurveda Ltd has a market capitalization of 673.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 121.47 Cr. However, it faced a loss of 13.03 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 32.16 Cr and Total Assets of 140.71 Cr.

Is Kerala Ayurveda technically bullish or bearish?

As of 29 October 2025, the market trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, as weekly indicators are mostly bearish while monthly indicators remain bullish.

As of 29 October 2025, the technical trend has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, indicating a divergence in momentum. The weekly Bollinger Bands are also mildly bearish, contrasting with the monthly Bollinger Bands which are mildly bullish. Moving averages on the daily chart show a mildly bullish stance, but the KST and Dow Theory are both bearish on the weekly and monthly charts. Overall, the indicators suggest a lack of clear direction, reinforcing the sideways trend.

How has been the historical performance of Kerala Ayurveda?

Kerala Ayurveda's historical performance has shown revenue growth from INR 58.90 crore in March 2019 to INR 120.33 crore in March 2025, but profitability has declined sharply, resulting in a net loss of INR -13.96 crore in March 2025. Despite positive cash flow from operations of INR 4.00 crore, the company faced significant challenges with an overall net cash outflow of INR -19.00 crore.

Answer:<BR>The historical performance of Kerala Ayurveda shows significant fluctuations over the years, particularly in revenue and profitability.<BR><BR>Breakdown:<BR>Kerala Ayurveda's net sales have shown a steady increase from INR 58.90 crore in March 2019 to INR 120.33 crore in March 2025. However, the total expenditure has also risen sharply, leading to an operating profit (PBDIT) that turned negative at INR -4.99 crore in March 2025, down from INR 8.83 crore in March 2024. This decline in profitability is reflected in the profit before tax, which fell to INR -12.24 crore in March 2025, compared to a profit of INR 0.66 crore in the previous year. Consequently, the profit after tax also dropped significantly to INR -13.96 crore in March 2025, indicating a challenging financial environment. The company's total assets decreased slightly to INR 123.99 crore in March 2025 from INR 128.47 crore in March 2024, while total liabilities also saw a decline to INR 123.99 crore from INR 128.47 crore. Cash flow from operating activities was positive at INR 4.00 crore in March 2025, but the overall net cash outflow was INR -19.00 crore, reflecting the company's struggles in managing its cash position effectively.

When is the next results date for Kerala Ayurveda Ltd?

The next results date for Kerala Ayurveda Ltd is 12 February 2026.

The next results date for Kerala Ayurveda Ltd is scheduled for 12 February 2026.

Should I buy, sell or hold Kerala Ayurveda Ltd?

Are Kerala Ayurveda Ltd latest results good or bad?

Kerala Ayurveda Ltd's latest results are poor, showing a consolidated net loss of ₹4.45 crore in Q3 FY26, a 53.98% increase from last year, alongside declining operational efficiency and a high debt-to-equity ratio of 15.49 times, indicating significant financial distress. Investors should exercise caution.

Kerala Ayurveda Ltd's latest results indicate a challenging financial situation. In Q3 FY26, the company reported a consolidated net loss of ₹4.45 crore, which is a significant increase of 53.98% compared to the same quarter last year. While net sales showed a modest growth of 5.88% year-on-year, reaching ₹32.96 crore, this growth is overshadowed by a decline of 5.40% compared to the previous quarter.<BR><BR>The operating margin has deteriorated further, now at -4.58%, compared to -3.82% in the same quarter last year. This indicates that the company is losing money on its core operations. Additionally, the debt-to-equity ratio is alarmingly high at 15.49 times, which is one of the highest in the pharmaceutical sector, raising concerns about financial stability.<BR><BR>Overall, the combination of persistent losses, declining operational efficiency, and high leverage suggests that the latest results are quite poor and reflect significant operational distress for Kerala Ayurveda. Investors should be cautious, as the company's financial health appears to be deteriorating.

Why is Kerala Ayurveda Ltd falling/rising?

As of 17-Mar, Kerala Ayurveda Ltd's stock price is rising to Rs. 175.65, up 6.23% after a trend reversal. However, it remains below all moving averages and has hit a new 52-week low, indicating ongoing volatility and declining investor confidence.

As of 17-Mar, Kerala Ayurveda Ltd's stock price is rising, currently at Rs. 175.65, reflecting an increase of Rs. 10.3 or 6.23%. This rise comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, the stock outperformed its sector by 5.95% today, indicating a relative strength compared to its peers.<BR><BR>Despite this positive movement, the stock has faced significant challenges recently, including a new 52-week low of Rs. 161.05 hit today. The stock has shown high volatility, with an intraday volatility of 5.55%, and has traded in a wide range of Rs. 18.95 throughout the day. Furthermore, it is currently trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), which typically suggests a bearish trend.<BR><BR>Investor participation has also been declining, with delivery volume falling by 23.8% against the 5-day average. This decrease in participation could indicate a lack of confidence among investors despite today's price increase. Overall, while the stock is experiencing a rise today, it is important to consider the broader context of its recent performance and the factors contributing to its volatility and declining investor interest.

Why is Kerala Ayurveda Ltd falling/rising?

As of 18-Mar, Kerala Ayurveda Ltd's stock price is at 185.90, reflecting a 5.84% increase today and a total return of 12.43% over the last two days. Despite recent gains, the stock has a year-to-date decline of 41.12% and shows high volatility, with declining investor participation indicated by a 46.75% drop in delivery volume.

As of 18-Mar, Kerala Ayurveda Ltd's stock price is rising, currently at 185.90, reflecting a change of 10.25 (5.84%) upwards. The stock has shown a positive performance today, outperforming its sector by 5.57% and has gained consecutively over the last two days, resulting in a total return of 12.43% during this period. Additionally, the stock opened with a gain of 3.02% today and reached an intraday high of Rs 199.8, which is a significant increase of 13.75%. <BR><BR>Despite the recent gains, it is important to note that the stock has experienced a decline over longer periods, with a year-to-date drop of 41.12% and a one-year decline of 50.27%. However, the current upward movement is characterized by high volatility, with an intraday volatility of 6.87%. The stock's trading activity indicates a wide range of Rs 25.7, and while it has been trading above its 5-day moving averages, it remains below the longer-term moving averages of 20, 50, 100, and 200 days. <BR><BR>Investor participation appears to be declining, as evidenced by a significant drop in delivery volume by 46.75% compared to the 5-day average. Nonetheless, the stock remains liquid enough for trading, indicating some level of market interest. Overall, the combination of recent gains, sector outperformance, and high volatility contributes to the current rise in Kerala Ayurveda Ltd's stock price.

Why is Kerala Ayurveda Ltd falling/rising?

As of 19-Mar, Kerala Ayurveda Ltd's stock price is at 186.00, showing a slight increase but reflecting a significant year-to-date decline of 41.09% and a 51.09% drop over the past year. Despite recent short-term gains, the stock's long-term trend remains downward, compounded by decreased investor participation.

As of 19-Mar, Kerala Ayurveda Ltd's stock price is currently at 186.00, reflecting a slight increase of 0.1 (0.05%). The stock has been gaining for the last three days, resulting in a total return of 12.49% during this period, which indicates a positive momentum. Additionally, it has outperformed its sector by 2.2% today, suggesting that the stock is experiencing some strength relative to its peers.<BR><BR>However, despite this recent uptick, the stock has shown significant declines over longer periods. Year-to-date, it has fallen by 41.09%, and over the past year, it has decreased by 51.09%. These substantial declines indicate that the stock has been under pressure over time, even as it experiences short-term gains.<BR><BR>The stock's current price is higher than its 5-day moving average, which is a positive sign, but it remains below its longer-term moving averages (20-day, 50-day, 100-day, and 200-day), suggesting that the overall trend may still be downward. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 40.85% compared to the 5-day average, which could indicate waning interest among investors.<BR><BR>In summary, while Kerala Ayurveda Ltd is currently experiencing a short-term rise in its stock price, the broader context reveals significant long-term declines and reduced investor engagement, which may temper the optimism surrounding its recent performance.

Why is Kerala Ayurveda Ltd falling/rising?

As of 20-Mar, Kerala Ayurveda Ltd's stock price is at 184.70, down 0.7% after a trend reversal following three days of gains. The stock has significantly underperformed its sector and experienced a sharp decline in investor participation, contributing to its ongoing losses of 41.50% year-to-date.

As of 20-Mar, Kerala Ayurveda Ltd's stock price is currently at 184.70, reflecting a decrease of 1.3 points or 0.7%. The stock has shown a trend reversal after three consecutive days of gains, indicating a shift in momentum. Although it opened with a gain of 2.12% today and reached an intraday high of Rs 193.15, it subsequently fell to a low of Rs 182, demonstrating volatility within the trading day.<BR><BR>The stock's performance today underperformed the sector by 2.4%, which may have contributed to the downward pressure on its price. Additionally, there has been a significant decline in investor participation, with delivery volume dropping by 83.23% compared to the five-day average. This lack of engagement could signal reduced confidence among investors, further exacerbating the stock's decline.<BR><BR>Over the longer term, the stock has faced substantial losses, with a year-to-date decrease of 41.50% and a one-year decline of 50.08%. These figures highlight ongoing challenges for the company, which may be influencing current trading behavior. Overall, the combination of a trend reversal, underperformance relative to the sector, and falling investor participation are key factors contributing to the stock's current decline.

Which are the latest news on Kerala Ayurveda?